VRTX to Strengthen Rare Disease Portfolio With $10B Crinetics Buyout
Zacks Equity Research
Tue, July 7, 2026 at 6:56 PM GMT+5:30
3 min read
- VRTX
-1.18% - NBIX
+2.27% - CRNX
-0.47%
Vertex PharmaceuticalsVRTX announced that it has agreed to acquire commercial-stage company Crinetics PharmaceuticalsCRNX. Per the terms, the large-cap biotech will acquire all outstanding shares of CRNX for $85 per share, valuing the deal at around $10 billion
Following the acquisition, Vertex will add Palsonify — Crinetics’ first marketed drug and the first once-daily oral therapy for adults with acromegaly, a rare and debilitating condition caused by a pituitary tumor that secretes excess growth hormone. Approved by the FDA in September 2025 and across the EU in April 2026, Palsonify has demonstrated encouraging early commercial uptake and is expected to benefit from Vertex’s global commercial infrastructure
The company will also add several pipeline candidates, including Crinetics’ lead pipeline candidate, atumelnant, which is currently in phase III development for congenital adrenal hyperplasia (CAH). The drug is also being developed in a mid-stage study for ACTH-dependent Cushing’s syndrome. Beyond atumelnant, the acquisition will add several earlier-stage endocrine assets discovered using Crinetics’ proprietary platform, further strengthening Vertex’s long-term pipeline
The transaction, unanimously approved by the boards of both companies, is expected to close in the third quarter. The company expects to fund the deal through a combination of cash and debt
VRTX & CRNX Stock Performance
Post the announcement, shares of Vertex were slightly down in pre-market trading today, while those of Crinetics have jumped nearly 99%
Year to date, VRTX’s stock is up nearly 17%, while CRNX is down about 10%. In comparison, the industry has risen 7% during this time frame
Image
What Drives Vertex’s Interest in Crinetics?
While Vertex expects the acquisition to contribute immediately to revenue growth, it believes the deal will become accretive to adjusted operating income beginning in 2029
The acquisition is expected to establish endocrinology as Vertex’s fifth core therapeutic area, alongside cystic fibrosis, hematology, acute pain and renal diseases, further diversifying the company’s rare disease portfolio. Management believes the transaction will add assets with a combined peak annual sales potential of more than $5 billion, driven by blockbuster sales potential for Palsonify and multibillion-dollar potential for atumelnant
A key attraction for Vertex is atumelnant, which management believes could emerge as the new standard-of-care for CAH. During the conference call, executives highlighted its potential to achieve normal androgen levels while allowing patients to remain on physiologic glucocorticoid replacement doses. Vertex believes this profile could differentiate atumelnant from currently available therapies, including Neurocrine Biosciences‘ NBIX Crenessity, describing this combination of outcomes as the “holy grail” of CAH management.
